Comparative Pharmacology
Head-to-head clinical analysis: CYCLAINE versus LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAINE versus LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5.
CYCLAINE vs LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclaine is a local anesthetic that reversibly blocks nerve conduction by decreasing the permeability of the neuronal membrane to sodium ions, thereby stabilizing the membrane and preventing the initiation and transmission of electrical impulses.
Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting phase 0 depolarization and decreasing automaticity in ventricular myocardial cells. It also has local anesthetic properties by blocking nerve impulse conduction.
0.2–0.4 mg/kg IV for induction; 0.5–1.5 mg/kg/h IV infusion for maintenance.
Intravenous infusion: 1-4 mg/min (0.25-1 mL/min of 0.4% solution) after a loading dose of 1-1.5 mg/kg IV bolus for ventricular arrhythmias. Maximum total dose: 3 mg/kg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged with hepatic impairment.
Terminal elimination half-life is approximately 1.5-2 hours (mean 1.8 h) in healthy adults. In patients with hepatic impairment or heart failure, half-life may be prolonged to >3 hours. In neonates, half-life can be 3-6 hours.
Renal: minimal (<5% unchanged); biliary/fecal: >70% as metabolites; small amount exhaled as CO2.
Renal excretion of metabolites (primarily monoethylglycinexylidide and glycinexylidide) accounts for >90% of elimination. Less than 10% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)